Abstract
Introduction Data on vaccine effectiveness (VE) against Omicron in adolescents are limited. We estimated 2-dose and 3-dose VE against Omicron and Delta in adolescents aged 12-17 years in Ontario, Canada.
Methods We conducted a test-negative design study among SARS-CoV-2-tested adolescents aged 12-17 years between November 22, 2021 (date of first Omicron detection) and March 6, 2022; we assessed Delta outcomes prior to January 2, 2022. We used multivariable logistic regression to compare the odds of vaccination in cases to symptomatic test-negative controls and calculated VE as 1-adjusted odds ratio.
Results VE was lower against symptomatic Omicron infection than against Delta and decreased more rapidly over time, from 51% (95%CI, 38-61%) in the 7-59 days following a second dose to 29% (95%CI, 17-38%) after 180 days, compared to 97% (95%CI, 94-99%) and 90% (95%CI, 79-95%) for the same intervals against symptomatic Delta infection. Overall, 2-dose VE against severe outcomes caused by Omicron was 85% (95%CI, 74-91%) ≥7 days following a second dose and estimates were similar over time. VE against symptomatic Omicron infection was 62% (95%CI, 49-72%) ≥7 days following a third dose.
Discussion Two-dose VE against symptomatic Omicron infection wanes over time in adolescents. While lower than observed against Delta, protection against severe outcomes appears to be maintained over time. A third dose substantially improves protection against Omicron infection, but 3-dose VE is only moderate at approximately 60% in the early period following vaccination and the duration of this protection is unknown.
Introduction
There are limited data on vaccine effectiveness (VE) against Omicron in adolescents. In Ontario, Canada, most vaccinated adolescents completed their primary series of BNT162b2 during summer 2021; third dose eligibility (6 months following a second dose) expanded to those aged 12-17 years in February 2022. We estimated 2-dose and 3-dose VE against Omicron and Delta for this age group.
Methods
We conducted a test-negative design among individuals aged 12-17 years and SARS-CoV-2-tested between November 22, 2021 (date of first Omicron detection) and March 6, 2022 using methods detailed elsewhere.1,2 We assessed Delta outcomes prior to January 2, 2022. We linked and analyzed laboratory, vaccination, reportable disease, and health administrative data for the entire eligible population at ICES. We estimated VE against symptomatic infection and severe outcomes (i.e., hospitalization or death) over time since second or third dose receipt for both Omicron and Delta, which were defined using a combination of whole genome sequencing and S-gene target failure results, and dates (Supplementary Table 1).2 In a sensitivity analysis, we estimated VE against symptomatic Omicron infection before and after restrictions to PCR test eligibility. We used multivariable logistic regression to compare the odds of vaccination in cases to symptomatic test-negative controls and calculated VE as 1-adjusted odds ratio.
Number of Omicron and Deltaa symptomatic infections by laboratory testing categorization during the period November 22, 2021 to March 6, 2022
Ethics approval
ICES is a prescribed entity under Ontario’s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES’ Privacy and Legal Office.
Results
We included 9,902 Omicron cases and 502 Delta cases (Supplementary Table 2). For the Omicron analyses, 91% of tested subjects had received two doses and 1.3% had received three doses (Supplementary Table 3). VE was lower against symptomatic Omicron infection than against Delta and decreased more rapidly over time, from 51% (95%CI, 38-61%) in the 7-59 days following a second dose to 29% (95%CI, 17-38%) after 180 days, compared to 97% (95%CI, 94-99%) and 90% (95%CI, 79-95%) for the same intervals against symptomatic Delta infection (Figure 1, Supplementary Table 4). Overall, 2-dose VE against severe outcomes due to Omicron was 85% (95%CI, 74-91%) ≥7 days following a second dose and estimates were similar over time. Although we were unable to assess 3-dose VE against severe Omicron outcomes or any Delta outcomes due to small numbers, VE against symptomatic Omicron infection was 62% (95%CI, 49-72%) ≥7 days following a third dose. Results against symptomatic Omicron infection were similar before and after changes to test eligibility criteria (Supplementary Table 5 and Supplementary Figure 1).
Descriptive characteristics of subjects tested for SARS-CoV-2 with COVID-19-relevant symptoms during the period November 22, 2021 to March 6, 2022 comparing Omicron cases and Delta cases with SARS-CoV-2-negative controls
Descriptive characteristics of subjects tested for SARS-CoV-2 with COVID-19-relevant symptoms during the period November 22, 2021 to March 6, 2022, comparing subjects with two doses, three doses and unvaccinated subjects, Omicron cases and SARS-CoV-2-negative controls only
Estimates of vaccine effectivenessa against symptomatic infection or severe outcomes (hospitalization or death) caused by Omicron or Deltab during the period November 22, 2021 to March 06, 2022, by time since latest dose
Characteristics of subjects tested for SARS-CoV-2 with COVID-19-relevant symptoms during the period November 22, 2021 to March 6, 2022, before and after PCR testing restrictions, Omicron cases and SARS-CoV-2-negative controls only
Estimates of vaccine effectivenessa against symptomatic infection caused by Omicron during the period November 22, 2021 to March 6, 2022, by time since latest dose, before and after PCR testing restrictions
aVaccine effectiveness estimates adjusted for: age, sex, public health unit region of residence, comorbidities, influenza vaccination status during the 2019/2020 and/or 2020/2021 influenza seasons, positive test >90 days before index date, week of testing, and neighbourhood-level information on median household income, proportion of the working population employed as non-health essential workers, mean number of persons per dwelling, and proportion of the population who self-identify as a visible minority.
Estimates of vaccine effectivenessa against symptomatic infection or severe outcomes (hospitalization or death) caused by Omicron or Deltab during the period of November 22, 2021 to March 6, 2022, by time since latest dose
aVaccine effectiveness estimates adjusted for: age, sex, public health unit region of residence, comorbidities, influenza vaccination status during the 2019/2020 and/or 2020/2021 influenza seasons, positive test >90 days before index date, week of testing, and neighbourhood-level information on median household income, proportion of the working population employed as non-health essential workers, mean number of persons per dwelling, and proportion of the population who self-identify as a visible minority.
bDelta outcomes were restricted to January 2, 2022 or prior due to small numbers and limited circulation after that date.
Discussion
VE against symptomatic Omicron infection wanes over time in adolescents given 2-doses of BNT162b2 and was higher following a third dose. While lower than observed against Delta, protection against severe outcomes appears to be maintained over time. The declining VE against infection is similar to results from England, where VE against Omicron and Delta in adolescents aged 16-17 years decreased from 76% and 93% after 7-13 days to 23% and 84% ≥70 days post second dose, respectively.3 In the US, 2-dose VE against Omicron hospitalization for those aged 12-15 and 16-17 years was 92% and 94% after 14-149 days compared to 73% and 88% after ≥150 days, respectively.4 This difference in VE over time since second dose was not statistically significant, whereas declines in VE against emergency department (ED) visits were. VE against ED visits increased following a third dose in those aged 16-17 years.4 Limitations of this study included an inability to classify some specimens using SGTF or sequencing, changes to test eligibility over the study period, and potential unmeasured confounding between vaccinated and unvaccinated individuals. These results can inform third dose recommendations in adolescents, as 2-dose protection against symptomatic Omicron infection is relatively low and wanes over time, whereas protection of a second dose against severe outcomes is higher. A third dose substantially improves protection against Omicron infection in adolescents, but 3-dose VE is only moderate at approximately 60% in the early period following vaccination and the duration of this protection is unknown. Understanding the impact of a third dose on improved protection against severe outcomes will be important.
Data Availability
The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das{at}ices.on.ca).
Data availability
The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das{at}ices.on.ca).
Code availability
The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.
Author contributions
S.A.B. and J.C.K. designed the study. L.N. obtained the data and conducted all analyses (data set and variable creation and statistical modelling). S.A.B. and J.C.K. drafted the manuscript. All authors contributed to the analysis plan, interpreted the results, critically reviewed and edited the manuscript, approved the final version, and agreed to be accountable for all aspects of the work.
Competing interests
The authors declare no conflicts of interest.
Funding and disclaimers
This work is supported by the Applied Health Research Questions (AHRQ) Portfolio at ICES, which is funded by the Ontario Ministry of Health. For more information on AHRQ and how to submit a request, please visit www.ices.on.ca/DAS/AHRQ. This work is also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario’s ongoing response to COVID-19 and its related impacts. This work was also supported by Public Health Ontario. J.C.K. is supported by Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine.
The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI), the Ontario Ministry of Health, and by Ontario Health (OH). Population estimates were adapted from Statistics Canada. However, the analyses, conclusions, opinions and statements expressed herein are solely those of the authors, and do not reflect those of the funding or data sources; no endorsement by ICES, MOH, MLTC, the Province of Ontario, CIHI, OH, or Statistics Canada is intended or should be inferred.
Acknowledgments
We would like to acknowledge Public Health Ontario for access to vaccination data from COVaxON, case-level data from CCM and COVID-19 laboratory data, as well as assistance with data interpretation. We also thank the staff of Ontario’s public health units who are responsible for COVID-19 case and contact management and data collection within CCM. We thank IQVIA Solutions Canada Inc. for use of their Drug Information Database. The authors are grateful to the Ontario residents without whom this research would be impossible.